Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials Abstract #2112

Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Aim(s): The present post-hoc pooled analysis was conducted to explore the potential impact of these events on efficacy of EVE.
Materials and methods: Patients (Pts) with advanced, low-, or intermediate-grade pancreatic (p), gastrointestinal (GI), or lung NETs received either EVE 10 mg/day oral or placebo in RADIANT-3 (p; N=207, N=203) and RADIANT-4 (GI or lung; N=205, N=97) trials. Key study outcomes were progression-free survival (PFS), duration of exposure, and safety. A landmark analysis of PFS (central review) was performed on pts treated for at least 16 weeks (wks; N=308 [n=200/412]) and according to occurrence of any-grade adverse events (AEs) within this treatment period.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Nicola Fazio

To read results and conclusion, please login ...

Further abstracts you may be interested in

#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Herbert A. Schmid
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...
#51 Epidemiology of the neuroendocrine tumors diagnosed in Cardarelli Hospital: a retrospective single-institution analysis of 274 cases
Introduction: Neuroendocrine tumors (NETs) are considered rare tumors and are characterized by their ability to produce peptides that cause typical hormonal syndromes. Neuroendocrine tumors consist of a wide spectrum of malignancies with different histology that can arise from distributed neuroendocrine cells in the body. Although these tumors are frequently indolent, they can be aggressive and resistant to therapy. Its incidence in the U.S.A has been rising in the last three decades (Surveillance, Epidemiology, and End Results registry). NETs are more common than generally believed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ferdinando Riccardi
#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Anna Koumarianou